Go to main content

Nordic Urothelial Cancer Oncology Group

Nordic Urothelial Cancer Oncology Group (NUCOG) is a collaborative network between medical oncologists in Finland, Norway, Sweden and Denmark.

View photos from previous NUCOG meetings

Dissemination activities of bladder cancer research

Poster presentation at ESMO 2018, München 19-23 October, Abstract: Feasibility of electronic reporting of patient reported outcomes for urothelial cancer patients receiving immunotherapy or chemotherapy. Presenter: Gry Assam Taarnhøj.

Poster presentation at ISOQOL 2018, Dublin 23-27 October, Abstract: Quality of life in bladder cancer patients receiving chemotherapy; a real life experience. Presenter: Gry Assam Taarnhøj.

Poster presentation at EAU 2018, Copenhagen, 18 March 15.45-17.15, Abstract nb 798: Patient-reported outcomes in bladder cancer; a multicentre randomized controlled trial – a study design. Presenter: Gry Assam Taarnhøj.

Poster presentation at EMUC 2013 Marseille, France - Vinflunine as second line chemotherapy for patients with metastatic urothelial cancer - A Nordic multi-center retrospective study. Presenter: Karin Holmsten.

Poster presentation at EMUC 2017 Barcelona, Spain - A multicenter, randomized phase II trial of vinflunine and gemcitabine versus carboplatin and gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal function - VINGEM.

Poster presentation at MASCC 2019, San Francisco 20-23 June: 'Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy’ Presenter: Gry Assam Taarnhøj.